Melanoma
Commentary
Do Infants Fed Rice and Rice Products Have an Increased Risk for Skin Cancer?
Rice and rice products, such as rice cereal and rice snacks, contain inorganic arsenic. Exposure to arsenicin utero and during early life may be...
Video
Must-Have Dermatology App for Skin Cancer Detection: Report From the Mount Sinai Fall Symposium
Dr. Daniel Siegel discusses the value of the SkinVision app for skin cancer detection. This app is available in Europe and Australia and is...
Video
Imaging Overview: Report From the Mount Sinai Fall Symposium
Dr. Daniel Siegel provides an overview of imaging in dermatology including the value of optical coherence tomography for diagnosing and...
Military Dermatology
Skin Cancer in Military Pilots: A Special Population With Special Risk Factors
Military pilots may be at greater risk for skin cancer, particularly melanoma. Military-specific studies are limited, but skin cancer rates in...
Video
Noninvasive Imaging: Report From the Mount Sinai Fall Symposium
Dr. Orit Markowitz reviews noninvasive imaging devices including dermoscopy, confocal microscopy, and optical coherence tomography. She explains...
Video
Color Wheel Approach to Diagnosing Skin Cancer: Report From the Mount Sinai Fall Symposium
Dr. Orit Markowitz discusses her dermoscopic approach to pursue very early cancerous lesions using a color wheel. She explains how colors are...
From the Journals
Lithium may reduce melanoma risk
Lithium exposure was associated with a lower risk of melanoma in a population-based study, which warrants further study, according to the...
Conference Coverage
Mitotic rate not tied to SLN biopsy results in thin melanomas
SAN FRANCISCO – A survey of melanoma cases showed no correlation between mitotic rate in thin tumors and positive sentinel lymph node biopsy.
From the Journals
Adding T-vec might help surmount PD-1 resistance in melanoma
Almost two-thirds of patients with advanced melanoma had at least a partial response and 33% had a complete response to combination therapy with...
Conference Coverage
COMBI-AD: Adjuvant combo halves relapses in BRAF V600-mutated melanoma
MADRID – The relapse-free survival curves separated early in the study, and at 1 year the rate of RFS was 88% among patients treated with the...
From the Journals
Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanoma
The rates of relapse-free survival were 71% at 12 months for patients assigned to adjuvant nivolumab, compared with 61% for adjuvant ipilimumab....